Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 763 | 126 | 616 |
| Samples | 378 | 79 | 292 |
| Peptides | 283 | 50 | 230 |
Function
AP1G2 · Adaptor related protein complex 1 subunit gamma 2
Adaptins are important components of clathrin-coated vesicles transporting ligand-receptor complexes from the plasma membrane or from the trans-Golgi network to lysosomes. The adaptin family of proteins is composed of four classes of molecules named alpha, beta-, beta prime- and gamma- adaptins. Adaptins, together with medium and small subunits, form a heterotetrameric complex called an adaptor, whose role is to promote the formation of clathrin-coated pits and vesicles. The protein encoded by this gene is a gamma-adaptin protein and it belongs to the adaptor complexes large subunits family. This protein along with the complex is thought to function at some trafficking step in the complex pathways between the trans-Golgi network and the cell surface. [provided by RefSeq, Aug 2017].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 283 amino-acid changes on canonical ENST00000397120 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in AP1G2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in AP1G2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Burkitts Lymphoma | 6/32 19% | 4/196 2% |
| Endometrial Carcinoma | 4/42 10% | 20/612 3% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Colorectal Carcinoma | 15/143 10% | 50/3239 2% |
| Non-Small Cell Lung Carcinoma | 17/304 6% | 8/1390 1% |
| Gastric Carcinoma | 0/74 0% | 27/1809 1% |
| Bladder Carcinoma | 0/58 0% | 12/956 1% |
| Chondrosarcoma | 1/14 7% | 0/75 0% |
| Melanoma | 0/210 0% | 23/1899 1% |
| Ovarian Carcinoma | 3/109 3% | 9/998 1% |
| Germ Cell Tumour | 0/25 0% | 2/169 1% |
| Osteosarcoma | 2/45 4% | 0/166 0% |
| Hepatocellular Carcinoma | 1/46 2% | 20/2210 1% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 6/810 1% |
| Cervical Carcinoma | 0/35 0% | 4/422 1% |
| Other Sarcomas | 0/69 0% | 6/699 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 12/1592 1% |
| Other Solid Cancers | 1/94 1% | 10/1515 1% |
| Breast Carcinoma | 5/144 3% | 17/3264 1% |
| Plasma Cell Myeloma | 0/44 0% | 2/305 1% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Head and Neck Carcinoma | 1/85 1% | 7/1574 0% |
| Other Blood Cancers | 4/61 7% | 8/2725 0% |
| Prostate Carcinoma | 0/13 0% | 9/2105 0% |
| Kidney Carcinoma | 0/85 0% | 8/1862 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 10/2550 0% |
Mutation Distribution
Where AP1G2 is mutated · all tissues, split by cell line vs tissue
How many mutations in AP1G2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 763 mutations in AP1G2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|